𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Farnesyltransferase inhibitors and anti-Ras therapy

✍ Scribed by Jackson B. Gibbs; Nancy E. Kohl; Kenneth S. Koblan; Charles A. Omer; Laura Sepp-Lorenzino; Neal Rosen; Neville J. Anthony; Michael W. Conner; S. Jane deSolms; Theresa M. Williams; Samuel L. Graham; George D. Hartman; Allen Oliff

Book ID
105314414
Publisher
Springer US
Year
1996
Tongue
English
Weight
737 KB
Volume
38
Category
Article
ISSN
0167-6806

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Farnesyltransferase inhibitors versus Ra
Farnesyltransferase inhibitors versus Ras inhibitors
✍ Jackson B Gibbs; Samuel L Graham; George D Hartman; Kenneth S Koblan; Nancy E Ko πŸ“‚ Article πŸ“… 1997 πŸ› Elsevier Science 🌐 English βš– 803 KB

Over the past few years, the idea that farnesyl-protein transferase (FPTase) inhibitors might be effective antiproliferative/antitumor agents has been realized in studies of cultured cells and in rodent models of cancer. Most of the studies with FPTase inhibitors have focused on inhibiting the growt

Selective GRB2 SH2 inhibitors as anti-Ra
Selective GRB2 SH2 inhibitors as anti-Ras therapy
✍ Brigitte Gay; StΓ©phanie Suarez; Giorgio Caravatti; Pascal Furet; Thomas Meyer; J πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 French βš– 218 KB

Given the key role of Ras in the mitogenic signaling by receptor tyrosine kinases, several targets upstream of Ras may prove to be excellent targets for drugs in the treatment of cancer caused by oncogenic tyrosine kinases. CGP78850 is a potent competitor of Grb2 SH2-phosphopeptide interactions. Thi